Pediatric Antidepressants and Anxiety Medicines

What Does the New Florida Guidance Recommend for Children?

The Sun Sentinel reports that new Florida guidance advises against using medicines to treat depression and anxiety in children. Such a broad recommendation differs from established pediatric mental-health guidance, which generally bases treatment on the child's specific diagnosis, symptom severity, functional impairment, suicide risk, coexisting conditions, treatment preferences, and access to psychotherapy.

The distinction matters because childhood depression and anxiety cover a wide clinical spectrum. Some children with mild symptoms may improve with supportive care and evidence-based psychotherapy, while those with persistent, moderate, or severe illness may need medication as part of a closely monitored treatment plan. Families should review the complete guidance with a qualified clinician rather than changing treatment in response to a headline.

When Are Antidepressants Used in Children and Adolescents?

For adolescent depression, the American Academy of Pediatrics' GLAD-PC guideline supports active monitoring for some mild presentations and evidence-based psychotherapy, medication, or their combination for more significant illness. Fluoxetine has an FDA-approved indication for major depressive disorder beginning at age 8, while escitalopram is approved for major depressive disorder beginning at age 12. Approval does not mean either medicine is appropriate for every young patient.

Cognitive behavioral therapy is an important treatment for pediatric anxiety disorders. Medication may be considered when anxiety is severe, substantially limits school or family life, prevents meaningful participation in therapy, or does not improve adequately with psychotherapy. Some prescribing is off-label, which is legally permitted and common in pediatrics but requires a clear evidence-based rationale, informed discussion, and careful follow-up.

How Should Young People Taking Antidepressants Be Monitored?

FDA antidepressant labeling carries a boxed warning about an increased risk of suicidal thinking and behavior in children, adolescents, and young adults during short-term studies. The warning calls for close observation; it does not establish that antidepressants should never be used. Clinicians should discuss warning signs with families and arrange follow-up appropriate to the patient's symptoms and level of risk.

Monitoring should include mood, anxiety, sleep, agitation, behavioral activation, adherence, school functioning, and suicidal thoughts or behavior. Clinicians should also assess for bipolar disorder and other conditions that could alter treatment. Antidepressants should not be stopped abruptly without medical advice because discontinuation symptoms and recurrence of the underlying illness can occur.